The Next Wave of Genetic Medicines for Rett Syndrome
We had a record turnout for our recent webinar and if you missed it, the full recording is now available.
Our CEO, Monica Coenraads, was joined by her colleagues for a wide-ranging conversation on everything happening right now in genetic medicine for Rett syndrome. The discussion introduced several biotech newcomers to the space, laid out timelines for upcoming clinical trials, and wrapped with an in-depth Q&A.
Our goal is to put ourselves out of business as quickly as possible.
Rare diseases don’t cure themselves. Developing genetic medicines is a complex, expensive effort with many moving parts. We are the organization orchestrating this global effort. Here is our plan to cure Rett syndrome.
Recently Diagnosed?
Getting a Rett syndrome diagnosis is one of the hardest things you’ll ever face. We know this first-hand. Emotions can run the gamut and it can all seem overwhelming. You’re worried about your child and your family. You’re reading everything you can get your hands on but unsure how to interpret it or if it's relevant. We’ve been there, just reach out to us: we’ve got your back.
The Summit
Over the course of three days in September we convened leading scientists, clinicians, and regulators to explore every corner of the genetic medicines landscape. The leadership from over 45 biopharma companies had a unique opportunity to hear about the state of Rett genetic medicine programs, with the ultimate goal of inspiring and motivating them to add the disorder to their pipelines.
This year’s gathering underscored RSRT’s role as both convener and catalyst, bringing brilliant minds together while never losing sight of the children and families at the heart of our community.
Latest News
Take Action
MECP2 Duplication
MECP2 Duplication syndrome (MDS) is caused by a genetic error that duplicates a section of the X chromosome that includes the MECP2 gene. The MECP2 Duplication Syndrome Fund at RSRT, created in 2010, puts the intellectual and scientific resources of RSRT immediately to work for the MDS community.
